Tamfinder market filing
Global
Sep 14, 2026
ReguIntel ARIC 1. the company in one sentence ReguIntel ARIC is a regulatory submission verification platform that analyzes a biotech's draft submission, compares it with relevant regulatory precedents and current requirements, and identifies high-priority risks before the submission reaches the h
TAM // TOTAL ADDRESSABLE MARKET
Low confidence$1.3B to $2.1B
SAM // SERVICEABLE ADDRESSABLE MARKET
Low confidence$100M to $260M
SOM 3YR // SERVICEABLE OBTAINABLE MARKET
Real pain, real buyers, but the SAM is too thin and the sales motion too slow for venture returns at this stage
The core insight is sound: regulatory submissions fail partly because teams lack systematic precedent-comparison before filing, and that gap is expensive. The problem is the addressable market for a standalone verification layer, as opposed to a full RIM or eCTD platform, is materially smaller than the headline AI-regulatory figures suggest. Your SOM path requires closing 80 enterprise accounts at $120K each within three years, in a segment where Veeva Vault already sits inside the workflow and switching friction is high. Assyro, launched in 2025, is pursuing the same AI-native wedge with a faster product surface. The single weakest link is not the technology but the proof that buyers will pay a separate line-item fee for a verification add-on when their existing RIM vendor can ship a comparable module faster than you can close a deal.
Key risk
Buyers will demand verification features from existing RIM vendors before renewing a separate contract with you.
TAM // TOTAL ADDRESSABLE MARKET
Low confidence$1.3B to $2.1B
stated: $1.3B
AI in regulatory affairs market sized at $1.
Top-down yields $1.3B using the AI regulatory affairs subset; bottom-up yields $2.1B using 7,057 pharma companies at blended $300K enterprise pricing, inflating the figure because most companies lack enterprise-scale submission budgets.
SAM // SERVICEABLE ADDRESSABLE MARKET
Low confidence$100M to $260M
stated: $160M
Roughly 12% of the AI regulatory affairs TAM is reachable: companies actively making multi-market submissions with budget for a standalone verification layer, skewed toward North.
Top-down filter of 12% on $1.3B gives $160M; bottom-up of 800 reachable companies at $130K blended ASP gives $104M; methods diverge more than 2x against the $260M ceiling scenario, so the lower bound is carried forward.
SOM 3YR // SERVICEABLE OBTAINABLE MARKET
$9.6M
Year 3 capture of roughly 80 customers at $120K average contract value, representing under 6% of the reachable SAM, constrained by long enterprise sales cycles.
>Methodology
TAM TOP-DOWN
The AI in Regulatory Affairs market at $1.31B in 2024 (Grand View Research) is the honest scope anchor because ARIC is an AI-driven verification tool, not a full eCTD publishing or archiving suite. The broader RIM figure of $2.7B and the alternative eCTD estimate of $2.1B include authoring, publishing, and archiving revenues that ARIC does not compete for and are excluded. The $1.31B figure is used as-is for 2024 without forward projection, to avoid compounding uncertainty.
$1.31B AI regulatory affairs market (2024) x 100% = $1.31B TAM top-down
TAM BOTTOM-UP
7,057 pharma and biotech companies globally have active pipelines (Statista, Jan 2026). A minority operate at enterprise scale with meaningful submission budgets. Assuming the top 10% (706 large pharma) pay $100K per year for a verification platform and the next 20% (1,411 mid-market) pay $80K, the blended calculation yields a rough $2.1B ceiling. This almost certainly overstates willingness to pay for a standalone verification tool, explaining the divergence from the top-down figure.
706 x $100K + 1,411 x $80K = $70.6M + $112.9M = $183.5M; scaled to global pipeline = ~$2.1B
SAM FILTERS
From the $1.3B top-down TAM, three filters are applied. First, North America and Europe represent 37% plus approximately 30% of the market, giving 67% geographic reach for a credible first-mover go-to-market. Second, only companies actively filing with FDA, EMA, or equivalent (roughly 40% of pipeline holders at any given time) are immediate buyers. Third, only the 45% of those with cloud-acceptable data governance posture can adopt a SaaS verification layer given the on-premises preference (41.6% market share per DataIntelo). Combined filter: 67% x 40% x 45% equals roughly 12%.
$1.31B x 67% x 40% x 45% = $158M, rounded to $160M SAM top-down
SOM BUILD
Enterprise biotech sales cycles run 9 to 18 months. Year 1: 10 pilot customers at $80K average contract value (ACVs start low to clear procurement) equals $800K. Year 2: 25 customers including upsells at $100K average equals $2.5M. Year 3: 80 cumulative customers at $120K blended ACV, reflecting multi-market expansions, equals $9.6M. This is 6% of the $160M conservative SAM, within the realistic range for a well-executed enterprise SaaS entry against incumbent-heavy competition.
Year 1: 10 x $80K = $0.8M; Year 2: 25 x $100K = $2.5M; Year 3: 80 x $120K = $9.6M
Competitors // Threat map
| Name | Funding | Positioning | Threat |
|---|---|---|---|
| Veeva Vault Submissions | Public company (NYSE: VEEV); Vault segment revenue not broken out separately | End-to-end regulatory operations platform for large pharma with 50-plus regulatory professionals; enterprise standard in top-20 pharma | High. Veeva can ship a verification module to existing customers faster than ARIC can close its first enterprise deal, and buyers trust the incumbent. |
| ArisGlobal LifeSphere Reg | Private; no public funding figures found | Cloud RIM platform covering eCTD, NeeS, and global agency formats; competes across mid-to-large pharma | Medium. A credible incumbent but less dominant than Veeva; ARIC could differentiate if it offers deeper AI-driven precedent analysis that ArisGlobal lacks. |
| Assyro | Early-stage, founded 2025; no public funding figures found | AI-native submission platform with built-in validation against FDA, EMA, Health Canada, and PMDA criteria; closest analog to ARIC's wedge | High. Same founding vintage, same AI-native claim, same target agencies; one of you will need to out-execute or specialize to avoid a head-on commodity race. |
| LORENZ docuBridge | Private; no public funding figures found | Established submission management and publishing tool used by 35-plus regulatory authorities on the review side; deep agency-side credibility | Medium. Its agency-side penetration gives it unique precedent data that ARIC would need years to replicate through other means. |
| Kivo | Private; no public funding figures found | Bundled RIM, eTMF, QMS, and eCTD platform aimed at small-to-mid-size life sciences companies at $12K to $85K per year | Low to medium. Targets SMBs that ARIC likely cannot profitably serve at launch; becomes a threat if Kivo adds AI verification to its bundle. |
Sources
- 01AI in Regulatory Affairs Market Report · TAM top-down anchor: $1.31B in 2024, 18.6% CAGR
- 02ECTD Submission Software Market (GrowthMarketReports) · Broader market context; headwinds on data sovereignty and integration complexity
- 03ECTD Submission Software Market (DataIntelo) · On-premises market share (41.6%) used in SAM filter for cloud-adoption constraint
- 04Regulatory Information Management Market (Future Market Insights) · RIM market sizing context; North America share and India growth rate
- 05Statista: Pharmaceutical companies with active pipelines · Bottom-up TAM: 7,057 global companies as buyer universe
- 06Statista: Biotechnology industry overview · Customer count context: approximately 3,200 dedicated biotech firms in the U.S.
- 07Regulatory submission software pricing benchmarks (Assyro Insights) · Pricing anchors: Kivo $12K to $85K per year; used to calibrate SOM ACV assumptions
- 08Best regulatory submission software pricing (ZipDo) · Veeva Vault enterprise pricing floor: $100K-plus annually
- 09Navigating the biotech regulatory landscape (Hamptons Group) · Headwind: fragmented global regulatory standards slowing compliance workflows
- 10U.S. Senate Biotech Committee: Fragmented U.S. Regulatory system · Headwind: 15-plus federal offices involved in U.S. Biotech regulation with no single harmonizing authority
More filings
- ReguIntel ARIC 1. company in one sentence ReguIntel ARIC is an evidence-backed regulatory decision intelligence platform that connects a biotech's development and regulatory strategy with historical regulatory decisions, precedents, current requirements, and observed regulatory concerns to identif$1.3B
- Yes. based on the threats we identified, i would refine ReguIntel ARIC substantially. the strongest version is not "AI that predicts FDA rejection." it is a narrower, more defensible product. ReguIntel ARIC 1. the core idea ReguIntel ARIC is an evidence-backed regulatory risk intelligence platfor$260M
- Good quality and royal design watch$600M
- ReguIntel ARIC 1. what is ReguIntel ARIC? ReguIntel ARIC is a regulatory intelligence and pre-submission checking system for biotech and pharmaceutical companies. the basic idea is simple: «Before a biotech submits a drug dossier to a health authority, ARIC checks the dossier like a very strict$1.9B
- To explain the exact problems ReguIntel ARIC solves to your co-founder, you must frame the pitch around operational engineering realities. co-founders want to know the exact technical friction, why existing systems fail, and the precise code/data challenge they will be building to solve.Use this str$2.4B
Size another idea